Skip to main content
Top
Published in: Gut Pathogens 1/2024

Open Access 01-12-2024 | Ulcerative Colitis | Research

Constituents of stable commensal microbiota imply diverse colonic epithelial cell reactivity in patients with ulcerative colitis

Authors: Ruta Inciuraite, Rolandas Gedgaudas, Rokas Lukosevicius, Deimante Tilinde, Rima Ramonaite, Alexander Link, Neringa Kasetiene, Mindaugas Malakauskas, Gediminas Kiudelis, Laimas Virginijus Jonaitis, Juozas Kupcinskas, Simonas Juzenas, Jurgita Skieceviciene

Published in: Gut Pathogens | Issue 1/2024

Login to get access

Abstract

Background

Despite extensive research on microbiome alterations in ulcerative colitis (UC), the role of the constituent stable microbiota remains unclear.

Results

This study, employing 16S rRNA-gene sequencing, uncovers a persistent microbial imbalance in both active and quiescent UC patients compared to healthy controls. Using co-occurrence and differential abundance analysis, the study highlights microbial constituents, featuring Phocaeicola, Collinsella, Roseburia, Holdemanella, and Bacteroides, that are not affected during the course of UC. Co-cultivation experiments, utilizing commensal Escherichia coli and Phocaeicola vulgatus, were conducted with intestinal epithelial organoids derived from active UC patients and controls. These experiments reveal a tendency for a differential response in tight junction formation and maintenance in colonic epithelial cells, without inducing pathogen recognition and stress responses, offering further insights into the roles of these microorganisms in UC pathogenesis. These experiments also uncover high variation in patients’ response to the same bacteria, which indicate the need for more comprehensive, stratified analyses with an expanded sample size.

Conclusion

This study reveals that a substantial part of the gut microbiota remains stable throughout progression of UC. Functional experiments suggest that members of core microbiota – Escherichia coli and Phocaeicola vulgatus – potentially differentially regulate the expression of tight junction gene in the colonic epithelium of UC patients and healthy individuals.
Appendix
Available only for authorised users
Literature
1.
go back to reference GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.CrossRef GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.CrossRef
2.
go back to reference Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756–70.CrossRefPubMed Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756–70.CrossRefPubMed
4.
go back to reference Rendón MA, Saldaña Z, Erdem AL, Monteiro-Neto V, Vázquez A, Kaper JB, et al. Commensal and pathogenic Escherichia coli use a common pilus adherence factor for epithelial cell colonization. Proc Natl Acad Sci U S A. 2007;104:10637–42.CrossRefPubMedPubMedCentral Rendón MA, Saldaña Z, Erdem AL, Monteiro-Neto V, Vázquez A, Kaper JB, et al. Commensal and pathogenic Escherichia coli use a common pilus adherence factor for epithelial cell colonization. Proc Natl Acad Sci U S A. 2007;104:10637–42.CrossRefPubMedPubMedCentral
5.
go back to reference Scott H, Davies GJ, Armstrong Z. The structure of Phocaeicola Vulgatus sialic acid acetylesterase. Acta Crystallogr Sect D Struct Biol. 2022;78:647–57.CrossRef Scott H, Davies GJ, Armstrong Z. The structure of Phocaeicola Vulgatus sialic acid acetylesterase. Acta Crystallogr Sect D Struct Biol. 2022;78:647–57.CrossRef
6.
go back to reference Yang H, Mirsepasi-Lauridsen HC, Struve C, Allaire JM, Sivignon A, Vogl W, et al. Ulcerative Colitis-associated E. Coli pathobionts potentiate colitis in susceptible hosts. Gut Microbes. 2020;12:1847976.CrossRefPubMedPubMedCentral Yang H, Mirsepasi-Lauridsen HC, Struve C, Allaire JM, Sivignon A, Vogl W, et al. Ulcerative Colitis-associated E. Coli pathobionts potentiate colitis in susceptible hosts. Gut Microbes. 2020;12:1847976.CrossRefPubMedPubMedCentral
8.
go back to reference Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581–3.CrossRefPubMedPubMedCentral Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581–3.CrossRefPubMedPubMedCentral
9.
go back to reference Barnett D, Arts I, Penders J. microViz: an R package for microbiome data visualization and statistics. J Open Source Softw. 2021;6:3201.CrossRef Barnett D, Arts I, Penders J. microViz: an R package for microbiome data visualization and statistics. J Open Source Softw. 2021;6:3201.CrossRef
10.
11.
go back to reference Santoru ML, Piras C, Murgia A, Palmas V, Camboni T, Liggi S, et al. Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients. Sci Rep. 2017;7:9523.CrossRefPubMedPubMedCentral Santoru ML, Piras C, Murgia A, Palmas V, Camboni T, Liggi S, et al. Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients. Sci Rep. 2017;7:9523.CrossRefPubMedPubMedCentral
12.
go back to reference Moen AEF, Lindstrøm JC, Tannæs TM, Vatn S, Ricanek P, Vatn MH, et al. The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients. Sci Rep. 2018;8:17278.CrossRefPubMedPubMedCentral Moen AEF, Lindstrøm JC, Tannæs TM, Vatn S, Ricanek P, Vatn MH, et al. The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients. Sci Rep. 2018;8:17278.CrossRefPubMedPubMedCentral
13.
go back to reference Lo Sasso G, Khachatryan L, Kondylis A, Battey JND, Sierro N, Danilova NA, et al. Inflammatory bowel Disease-Associated Changes in the gut: focus on Kazan Patients. Inflamm Bowel Dis. 2021;27:418–33.CrossRefPubMed Lo Sasso G, Khachatryan L, Kondylis A, Battey JND, Sierro N, Danilova NA, et al. Inflammatory bowel Disease-Associated Changes in the gut: focus on Kazan Patients. Inflamm Bowel Dis. 2021;27:418–33.CrossRefPubMed
14.
go back to reference Alam MT, Amos GCA, Murphy ARJ, Murch S, Wellington EMH, Arasaradnam RP. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020;12:1.CrossRefPubMedPubMedCentral Alam MT, Amos GCA, Murphy ARJ, Murch S, Wellington EMH, Arasaradnam RP. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020;12:1.CrossRefPubMedPubMedCentral
15.
go back to reference Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–83.CrossRefPubMed Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–83.CrossRefPubMed
16.
go back to reference Shen Z-H, Zhu C-X, Quan Y-S, Yang Z-Y, Wu S, Luo W-W, et al. Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018;24:5–14.CrossRefPubMedPubMedCentral Shen Z-H, Zhu C-X, Quan Y-S, Yang Z-Y, Wu S, Luo W-W, et al. Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018;24:5–14.CrossRefPubMedPubMedCentral
17.
go back to reference Nishihara Y, Ogino H, Tanaka M, Ihara E, Fukaura K, Nishioka K, et al. Mucosa-associated gut microbiota reflects clinical course of ulcerative colitis. Sci Rep. 2021;11:13743.CrossRefPubMedPubMedCentral Nishihara Y, Ogino H, Tanaka M, Ihara E, Fukaura K, Nishioka K, et al. Mucosa-associated gut microbiota reflects clinical course of ulcerative colitis. Sci Rep. 2021;11:13743.CrossRefPubMedPubMedCentral
18.
go back to reference Öhman L, Lasson A, Strömbeck A, Isaksson S, Hesselmar M, Simrén M, et al. Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis. Sci Rep. 2021;11:8641.CrossRefPubMedPubMedCentral Öhman L, Lasson A, Strömbeck A, Isaksson S, Hesselmar M, Simrén M, et al. Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis. Sci Rep. 2021;11:8641.CrossRefPubMedPubMedCentral
19.
go back to reference Zhou Y, Zhi F. Lower Level of Bacteroides in the gut microbiota is Associated with Inflammatory Bowel Disease: a Meta-analysis. Biomed Res Int. 2016;2016:5828959.CrossRefPubMedPubMedCentral Zhou Y, Zhi F. Lower Level of Bacteroides in the gut microbiota is Associated with Inflammatory Bowel Disease: a Meta-analysis. Biomed Res Int. 2016;2016:5828959.CrossRefPubMedPubMedCentral
20.
go back to reference Mills RH, Dulai PS, Vázquez-Baeza Y, Sauceda C, Daniel N, Gerner RR, et al. Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat Microbiol. 2022;7:262–76.CrossRefPubMedPubMedCentral Mills RH, Dulai PS, Vázquez-Baeza Y, Sauceda C, Daniel N, Gerner RR, et al. Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat Microbiol. 2022;7:262–76.CrossRefPubMedPubMedCentral
21.
go back to reference de Meij TGJ, de Groot EFJ, Peeters CFW, de Boer NKH, Kneepkens CMF, Eck A, et al. Variability of core microbiota in newly diagnosed treatment-naïve paediatric inflammatory bowel disease patients. PLoS ONE. 2018;13:e0197649.CrossRefPubMedPubMedCentral de Meij TGJ, de Groot EFJ, Peeters CFW, de Boer NKH, Kneepkens CMF, Eck A, et al. Variability of core microbiota in newly diagnosed treatment-naïve paediatric inflammatory bowel disease patients. PLoS ONE. 2018;13:e0197649.CrossRefPubMedPubMedCentral
22.
go back to reference Elmassry MM, Sugihara K, Chankhamjon P, Camacho FR, Wang S, Sugimoto Y et al. A meta-analysis of the gut microbiome in inflammatory bowel disease patients identifies disease-associated small molecules. bioRxiv Prepr. Serv. Biol. United States; 2024. Elmassry MM, Sugihara K, Chankhamjon P, Camacho FR, Wang S, Sugimoto Y et al. A meta-analysis of the gut microbiome in inflammatory bowel disease patients identifies disease-associated small molecules. bioRxiv Prepr. Serv. Biol. United States; 2024.
23.
go back to reference Zakerska-Banaszak O, Tomczak H, Gabryel M, Baturo A, Wolko L, Michalak M, et al. Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot study. Sci Rep. 2021;11:2166.CrossRefPubMedPubMedCentral Zakerska-Banaszak O, Tomczak H, Gabryel M, Baturo A, Wolko L, Michalak M, et al. Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot study. Sci Rep. 2021;11:2166.CrossRefPubMedPubMedCentral
24.
go back to reference Elbing KL, Brent R. Recipes and tools for culture of Escherichia coli. Curr Protoc Mol Biol. 2019;125:e83.CrossRefPubMed Elbing KL, Brent R. Recipes and tools for culture of Escherichia coli. Curr Protoc Mol Biol. 2019;125:e83.CrossRefPubMed
25.
go back to reference Keitel L, Miebach K, Rummel L, Yordanov S, Büchs J. Process analysis of the anaerobe Phocaeicola vulgatus in a shake flasks and fermenter reveals pH and product inhibition. Ann Microbiol. 2024;74:7. Keitel L, Miebach K, Rummel L, Yordanov S, Büchs J. Process analysis of the anaerobe Phocaeicola vulgatus in a shake flasks and fermenter reveals pH and product inhibition. Ann Microbiol. 2024;74:7.
26.
go back to reference Puschhof J, Pleguezuelos-Manzano C, Martinez-Silgado A, Akkerman N, Saftien A, Boot C et al. Intestinal organoid cocultures with microbes. Nat Protoc. 2021;16:4633–49. Puschhof J, Pleguezuelos-Manzano C, Martinez-Silgado A, Akkerman N, Saftien A, Boot C et al. Intestinal organoid cocultures with microbes. Nat Protoc. 2021;16:4633–49.
27.
go back to reference Keitel L, Braun K, Finger M, Kosfeld U, Yordanov S, Büchs J. Carbon dioxide and trace oxygen concentrations impact growth and product formation of the gut bacterium Phocaeicola vulgatus. BMC Microbiol. 2023;23:391. Keitel L, Braun K, Finger M, Kosfeld U, Yordanov S, Büchs J. Carbon dioxide and trace oxygen concentrations impact growth and product formation of the gut bacterium Phocaeicola vulgatus. BMC Microbiol. 2023;23:391.
28.
go back to reference MJN V. T. WS. Escherichia coli residency in the gut of healthy human adults. EcoSal Plus. 2020;9. MJN V. T. WS. Escherichia coli residency in the gut of healthy human adults. EcoSal Plus. 2020;9.
29.
go back to reference Stromberg ZR, Van Goor A, Redweik GAJ, Wymore Brand MJ, Wannemuehler MJ, Mellata M. Pathogenic and non-pathogenic Escherichia coli colonization and host inflammatory response in a defined microbiota mouse model. Dis Model Mech. 2018;11. Stromberg ZR, Van Goor A, Redweik GAJ, Wymore Brand MJ, Wannemuehler MJ, Mellata M. Pathogenic and non-pathogenic Escherichia coli colonization and host inflammatory response in a defined microbiota mouse model. Dis Model Mech. 2018;11.
30.
go back to reference Neff A, Lück R, Hövels M, Deppenmeier U. Expanding the repertoire of counterselection markers for markerless gene deletion in the human gut bacterium Phocaeicola vulgatus. Anaerobe. 2023;81:102742. Neff A, Lück R, Hövels M, Deppenmeier U. Expanding the repertoire of counterselection markers for markerless gene deletion in the human gut bacterium Phocaeicola vulgatus. Anaerobe. 2023;81:102742.
31.
go back to reference Guttman JA, Finlay BB. Tight junctions as targets of infectious agents. Biochim Biophys Acta. 2009;1788:832–41.CrossRefPubMed Guttman JA, Finlay BB. Tight junctions as targets of infectious agents. Biochim Biophys Acta. 2009;1788:832–41.CrossRefPubMed
33.
go back to reference Liu L, Xu M, Lan R, Hu D, Li X, Qiao L, et al. Bacteroides vulgatus attenuates experimental mice colitis through modulating gut microbiota and immune responses. Front Immunol. 2022;13:1036196.CrossRefPubMedPubMedCentral Liu L, Xu M, Lan R, Hu D, Li X, Qiao L, et al. Bacteroides vulgatus attenuates experimental mice colitis through modulating gut microbiota and immune responses. Front Immunol. 2022;13:1036196.CrossRefPubMedPubMedCentral
34.
go back to reference Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–23.CrossRefPubMedPubMedCentral Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–23.CrossRefPubMedPubMedCentral
Metadata
Title
Constituents of stable commensal microbiota imply diverse colonic epithelial cell reactivity in patients with ulcerative colitis
Authors
Ruta Inciuraite
Rolandas Gedgaudas
Rokas Lukosevicius
Deimante Tilinde
Rima Ramonaite
Alexander Link
Neringa Kasetiene
Mindaugas Malakauskas
Gediminas Kiudelis
Laimas Virginijus Jonaitis
Juozas Kupcinskas
Simonas Juzenas
Jurgita Skieceviciene
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2024
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-024-00612-0

Other articles of this Issue 1/2024

Gut Pathogens 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.